S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

RCKT Rocket Pharmaceuticals Inc

9.035

0.375 (4.33%)

Last Updated: 05:18:28

Delayed by 15 minutes

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Rocket Pharmaceuticals Charts.

Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Rocket Pharmaceuticals Charts.

Rocket Pharmaceuticals Inc News

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
Friday 28 February 2025 (6 days ago) • Business Wire

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Friday 3 January 2025 (2 months ago) • Business Wire

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Wednesday 11 December 2024 (3 months ago) • Business Wire

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
Wednesday 11 December 2024 (3 months ago) • Business Wire

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
Tuesday 26 November 2024 (3 months ago) • Business Wire

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
Tuesday 19 November 2024 (4 months ago) • Business Wire

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
Wednesday 13 November 2024 (4 months ago) • Business Wire

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
Friday 8 November 2024 (4 months ago) • Business Wire

Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Friday 8 November 2024 (4 months ago) • Business Wire

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
Tuesday 17 September 2024 (6 months ago) • Business Wire

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
Tuesday 10 September 2024 (6 months ago) • Business Wire

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Tuesday 27 August 2024 (6 months ago) • Business Wire

More Rocket Pharmaceuticals Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions